FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:217-218 January 20, 2000 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Pizzo, P. A. PubMed Citation

To the Editor: Pizzo, in his review entitled "Fever in Immunocompromised Patients" (Sept. 16 issue),¹ states that immediate postoperative care for recipients of bone marrow transplants should be similar to the treatment of high-risk patients with cancer and that either single-agent or multiple-agent parenteral antibiotic therapy can be chosen. Single-agent antimicrobial therapy has not been well studied in recipients of bone marrow transplants, especially patients undergoing allogeneic transplantation. For instance, in the application submitted to the Food and Drug Administration for cefepime to be used as monotherapy for fever and neutropenia, more than 1200 patients with fever and neutropenia were . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.